Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen to raise capital for Phase II Alzhimer’s disease clinical study

Actinogen to raise capital for Phase II Alzhimer’s disease clinical study

Actinogen (ASX:ACW) is progressing development of its novel treatments for Alzheimer’s disease and other major age-related neurodegenerative disorders.

The company has now been granted an ASX trading halt in relation to a capital raising for a Phase II study in Alzheimer’s dementia.

This will last until the earlier of the announcement being made or the start of trade on Friday, 24th April 2015.

Actinogen’s lead drug candidate Xanamem is being developed as a new therapy for Alzheimer’s disease.

Earlier this month, the company successfully dosed the second cohort of Phase I trial participants with 20mg of Xanamem.

This led to its being granted approval to escalate the dose to 35mg for the final cohort.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Register here to be notified of future ACW Company articles
View full ACW profile View Profile

Actinogen Medical Ltd Timeline

December 30 2016

Related Articles

Regeneus: Access latest PPT from Proactive's CEO Sessions
June 19 2017
John Martin discussed regenerative medicine with investors.
picture of doctor
September 06 2017
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor
cancer cells
July 12 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use